Welcome to our dedicated page for Iradimed news (Ticker: IRMD), a resource for investors and traders seeking the latest updates and insights on Iradimed stock.
iRadimed Corporation reports news on its MRI-compatible medical-device business, including non-magnetic IV infusion pump systems, patient vital signs monitoring systems, accessories, disposables and related services sold to hospitals and acute care facilities. Company updates often describe financial results, revenue and earnings guidance, cash generation, and regular or special cash dividends.
IRMD news also covers product activity for systems such as the 3880 MRI-compatible patient vital signs monitor and the next-generation 3870 MRI-compatible IV infusion pump, along with investor conference participation and recognition tied to growth and financial performance.
IRADIMED (NASDAQ: IRMD) reported record Q2 2024 financial results, with revenue of $17.9 million, up 11.2% year-over-year. The company achieved GAAP diluted EPS of $0.38 and non-GAAP diluted EPS of $0.42. Operating income increased by 13.4% to $5.6 million. IRADIMED declared a quarterly cash dividend of $0.15 per share.
For Q3 2024, the company expects revenue between $18.0-$18.2 million and GAAP diluted EPS of $0.34-$0.37. The full-year 2024 guidance remains unchanged, with expected revenue of $72.0-$74.0 million and GAAP diluted EPS of $1.37-$1.47. The strong performance was driven by growth in the IV infusion pump product line and continued strength in gross margins.
IRADIMED (NASDAQ: IRMD) has announced its upcoming 2024 second quarter financial results conference call, scheduled for August 1, 2024. The company will release its financial results before the market opens on that day. The conference call, hosted by Iradimed management, will begin at 12:00 p.m. Eastern Time.
Interested individuals can participate by registering through the provided link. Upon registration, participants will receive a dial-in number, unique pin, and instructions. The call will also be available in real-time via the internet on Iradimed's investor relations website. A recording of the call will be made available on the company's website following its completion.
Iradimed (NASDAQ: IRMD), a leading provider of MRI-compatible medical devices, announced that its common stock will uplist to the Nasdaq Global Market starting June 14, 2024. This move reflects the company's growth and commitment to delivering value to shareholders. Roger Susi, CEO, emphasized that the uplisting enhances Iradimed's market visibility and aligns it with companies of high distinction. Iradimed was previously listed on the Nasdaq Capital Market since its IPO in 2014. The Nasdaq Global Market is known for its rigorous financial and corporate governance standards, including stocks of about 1,450 companies.
IRADIMED reported record revenue of $17.6 million, GAAP diluted EPS of $0.32, and non-GAAP diluted EPS of $0.36 for the first quarter of 2024. The company also declared a regular quarterly cash dividend of $0.15 per share for the second quarter of 2024. The financial results showed an increase in operating income by 18.5% compared to the same period in 2023. The company anticipates strong financial performance for the second quarter and full year of 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.